Format

Send to

Choose Destination
Lancet Oncol. 2015 Jan;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11.

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

Author information

1
San Camillo and Forlanini Hospitals, Rome, Italy. Electronic address: cstern@mclink.it.
2
Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland.
3
The Netherlands Cancer Institute, Amsterdam, Netherlands.
4
Klinikum Kassel, Kassel, Germany; University Clinic Bonn, Bonn, Germany.
5
Oslo University Hospital, Oslo, Norway.
6
Aarhus University Hospital, Aarhus, Denmark.
7
KU Leuven-University of Leuven, University Hospitals Leuven, Department of General Medical Oncology, Leuven, Belgium.
8
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna)-LB Cluster Translational Oncology (LB-CTO), Kaiser Franz Josef-Spital, Vienna, Austria.
9
Hôpital Foch, Suresnes, France; Institut Gustave Roussy, Villejuif, France.
10
St James's University Hospital, Leeds, UK.
11
St James's University Hospital, Leeds, UK; Cardiff University and Velindre Cancer Center, Cardiff, UK.
12
University Hospital Ghent, Ghent, Belgium.
13
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
14
QEII Health Sciences Centre, Dalhousie University Halifax, NS, Canada.
15
Radboud University Medical Center Nijmegen, Nijmegen, Netherlands.
16
Erasmus University Medical Center, Rotterdam, Netherlands.
17
Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre-Les-Nancy, France.
18
Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
19
Inselspital, Bern, Switzerland.
20
Centre Hospitalier de l'Université de Montreal-Hôpital Notre-Dame, Montreal, QC, Canada.
21
Institut de Cancérologie de l'Ouest-Centre Rene Gauducheau, St Herblain, Nantes, France.
22
Centre Médico-Chirurgical Foch, Suresnes, France.
23
Nottingham University Hospitals NHS Trust-City Hospital, Nottingham, UK.
24
Leicester Royal Infirmary, Leicester, UK.
25
University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
26
Centre François Baclesse, Caen, France.
27
EORTC Headquarters, Brussels, Belgium.

Abstract

BACKGROUND:

Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder.

METHODS:

This intergroup, open-label, randomised, phase 3 trial recruited patients from hospitals across Europe and Canada. Eligible patients had histologically proven urothelial carcinoma of the bladder, pT3-pT4 disease or node positive (pN1-3) M0 disease after radical cystectomy and bilateral lymphadenectomy, with no evidence of any microscopic residual disease. Within 90 days of cystectomy, patients were centrally randomly assigned (1:1) by minimisation to either immediate adjuvant chemotherapy (four cycles of gemcitabine plus cisplatin, high-dose methotrexate, vinblastine, doxorubicin, and cisplatin [high-dose MVAC], or MVAC) or six cycles of deferred chemotherapy at relapse, with stratification for institution, pT category, and lymph node status according to the number of nodes dissected. Neither patients nor investigators were masked. Overall survival was the primary endpoint; all analyses were by intention to treat. The trial was closed after recruitment of 284 of the planned 660 patients. This trial is registered with ClinicalTrials.gov, number NCT00028756.

FINDINGS:

From April 29, 2002, to Aug 14, 2008, 284 patients were randomly assigned (141 to immediate treatment and 143 to deferred treatment), and followed up until the data cutoff of Aug 21, 2013. After a median follow-up of 7.0 years (IQR 5.2-8.7), 66 (47%) of 141 patients in the immediate treatment group had died compared with 82 (57%) of 143 in the deferred treatment group. No significant improvement in overall survival was noted with immediate treatment when compared with deferred treatment (adjusted HR 0.78, 95% CI 0.56-1.08; p=0.13). Immediate treatment significantly prolonged progression-free survival compared with deferred treatment (HR 0.54, 95% CI 0.4-0.73, p<0.0001), with 5-year progression-free survival of 47.6% (95% CI 38.8-55.9) in the immediate treatment group and 31.8% (24.2-39.6) in the deferred treatment group. Grade 3-4 myelosuppression was reported in 33 (26%) of 128 patients who received treatment in the immediate chemotherapy group versus 24 (35%) of 68 patients who received treatment in the deferred chemotherapy group, neutropenia occurred in 49 (38%) versus 36 (53%) patients, respectively, and thrombocytopenia in 36 (28%) versus 26 (38%). Two patients died due to toxicity, one in each group.

INTERPRETATION:

Our data did not show a significant improvement in overall survival with immediate versus deferred chemotherapy after radical cystectomy and bilateral lymphadenectomy for patients with muscle-invasive urothelial carcinoma. However, the trial is limited in power, and it is possible that some subgroups of patients might still benefit from immediate chemotherapy. An updated individual patient data meta-analysis and biomarker research are needed to further elucidate the potential for survival benefit in subgroups of patients.

FUNDING:

Lilly, Canadian Cancer Society Research.

PMID:
25498218
DOI:
10.1016/S1470-2045(14)71160-X
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center